Cytogenetics (Bone Marrow Chromosomes) at Dr. Essa Lab

Cytogenetics (Bone Marrow Chromosomes) at Dr. Essa Lab

Cytogenetics (Bone Marrow Chromosomes) is a highly specialized laboratory investigation that analyzes the structure and number of chromosomes in bone marrow cells. This diagnostic procedure, commonly referred to as bone marrow karyotyping, is the gold standard for identifying acquired chromosomal abnormalities in patients with hematological disorders. By evaluating the genetic blueprint of blood-forming cells, cytogenetic analysis provides critical insights that are essential for the accurate diagnosis, classification, prognostication, and therapeutic monitoring of various leukemias, lymphomas, myelodysplastic syndromes, and other bone marrow disorders. Dr. Essa Lab, a premier diagnostic institution in Karachi, Pakistan, utilizes state-of-the-art cytogenetic technology and expert hematopathology analysis to deliver precise and reliable results for patients undergoing this critical evaluation.

Chromosomes are thread-like structures located inside the nucleus of every cell, carrying the genetic information (DNA) that governs cellular function and development. In healthy individuals, bone marrow cells contain 46 chromosomes arranged in 23 pairs. However, in hematological malignancies, genetic mutations can lead to numerical abnormalities (such as the gain or loss of entire chromosomes) or structural rearrangements (such as translocations, deletions, inversions, or duplications). The Cytogenetics (Bone Marrow Chromosomes) test at Dr. Essa Lab allows clinical pathologists and hematologists to visualize these chromosomes during metaphase, the phase of cell division where they are most condensed and clearly defined. This detailed genetic profiling is indispensable for modern personalized medicine, enabling oncologists to tailor treatment regimens to the specific genetic profile of a patient’s disease.

Clinical Procedure: What to Expect

Patient Preparation

Proper preparation is essential to ensure patient safety and the collection of a high-quality bone marrow sample. Patients scheduled for a bone marrow aspiration and subsequent cytogenetic analysis should observe the following guidelines:

• Medical History and Consultation: Inform your physician about all current medications, especially blood thinners, anticoagulants (such as warfarin, heparin, or direct oral anticoagulants), and antiplatelet drugs (such as aspirin or clopidogrel). Your doctor may advise you to temporarily suspend these medications prior to the procedure to minimize the risk of bleeding.
• Coagulation Profile: A complete blood count (CBC) and a coagulation profile (including PT, APTT, and INR) are typically performed before the procedure to evaluate the blood’s clotting ability.
• Dietary Instructions: Fasting is generally not required for a bone marrow aspiration. Patients are encouraged to eat a light meal and stay hydrated before the procedure to prevent dizziness or vasovagal episodes.
• Informed Consent: The clinical team will explain the procedure, potential risks, and benefits. You will be asked to sign an informed consent form prior to the initiation of the aspiration.
• Psychological Preparation: It is normal to feel anxious before a bone marrow aspiration. Discussing the procedure with your healthcare provider and understanding each step can help alleviate anxiety.

During the Procedure

The collection of the bone marrow sample is a sterile medical procedure performed by a qualified hematologist or clinical pathologist. The process involves several key steps:

• Patient Positioning: The patient is typically asked to lie on their side (lateral decubitus position) or on their stomach (prone position) on an examination table, exposing the posterior superior iliac spine (the back of the hip bone), which is the most common and safest site for aspiration.
• Sterilization and Local Anesthesia: The skin over the selected site is thoroughly cleansed with an antiseptic solution. A local anesthetic (such as lidocaine) is injected into the skin, subcutaneous tissues, and the periosteum (the sensitive outer membrane of the bone) to minimize discomfort.
• Sample Collection: Once the area is numb, the physician inserts a specialized bone marrow aspiration needle through the outer bone cortex into the marrow cavity. A syringe is attached to the needle, and a small volume (approximately 2 to 3 mL) of liquid bone marrow is aspirated. Patients may experience a brief, sharp, pulling sensation or deep ache during this aspiration phase.
• Specimen Handling: The aspirated bone marrow fluid is immediately transferred into a sterile tube containing sodium heparin. Heparin is critical because it prevents the sample from clotting, keeping the cells viable for the subsequent laboratory culture process.
• Post-Procedure Care: The needle is removed, and firm pressure is applied to the site for several minutes to stop any bleeding. A sterile bandage is then applied. The patient is advised to rest for a short period before returning home.

Laboratory Processing and Analysis

Once the bone marrow sample arrives at the cytogenetics department of Dr. Essa Lab, it undergoes a meticulous laboratory workflow:

• Cell Culture: The viable bone marrow cells are inoculated into specialized culture media and incubated at 37°C for 24 to 72 hours to encourage active cell division.
• Mitotic Arrest: A chemical agent called Colcemid is added to the culture to arrest the dividing cells in the metaphase stage of mitosis, when the chromosomes are highly condensed.
• Hypotonic Treatment and Fixation: The cells are treated with a hypotonic solution to make them swell, which helps spread the chromosomes. A fixative solution is then added to preserve the cellular structure.
• Slide Preparation and G-Banding: The cell suspension is dropped onto glass slides, dried, and stained using Giemsa stain (G-banding). This staining technique produces a unique pattern of dark and light bands along each chromosome, allowing for precise identification.
• Microscopic Evaluation: An experienced cytogeneticist analyzes at least 20 metaphase spreads under a high-resolution light microscope coupled with computerized imaging and karyotyping software to identify any structural or numerical abnormalities.

When is a Cytogenetics (Bone Marrow Chromosomes) Performed?

Acute Myeloid Leukemia (AML) Diagnosis and Classification

In patients suspected of having Acute Myeloid Leukemia (AML), cytogenetic analysis is an absolute clinical necessity. AML is a highly heterogeneous disease, and its classification under the World Health Organization (WHO) guidelines relies heavily on specific, recurrent cytogenetic abnormalities. Identifying translocations such as t(8;21), inv(16), or t(15;17) not only confirms the diagnosis but also categorizes the leukemia into specific prognostic subgroups. For instance, the detection of t(15;17) confirms Acute Promyelocytic Leukemia (APL), a medical emergency that requires immediate targeted therapy with all-trans retinoic acid (ATRA). Cytogenetics helps clinicians select the most effective chemotherapy regimens and determine whether a bone marrow transplant is indicated.

Chronic Myeloid Leukemia (CML) Monitoring

Chronic Myeloid Leukemia (CML) is characterized by the presence of the Philadelphia chromosome, which is a reciprocal translocation between chromosomes 9 and 22, designated as t(9;22)(q34.1;q11.2). This translocation fuses the ABL1 gene on chromosome 9 with the BCR gene on chromosome 22, resulting in an abnormal, constitutively active tyrosine kinase protein that drives uncontrolled cell division. Cytogenetics is performed at the initial diagnosis of CML to confirm the presence of the Philadelphia chromosome. Furthermore, it is performed periodically during treatment to monitor the patient’s cytogenetic response to tyrosine kinase inhibitors (TKIs) such as imatinib, nilotinib, or dasatinib, and to detect any clonal evolution or additional chromosomal abnormalities that might suggest disease progression or resistance to therapy.

Myelodysplastic Syndromes (MDS) Prognostication

Myelodysplastic Syndromes (MDS) represent a group of clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis, peripheral cytopenias, and a risk of transformation into AML. Cytogenetic abnormalities are detected in approximately 50% of patients with primary MDS. The specific chromosomal findings are a critical component of the Revised International Prognostic Scoring System (IPSS-R), which clinicians use to estimate survival and the risk of leukemia transformation. For example, an isolated deletion of the long arm of chromosome 5 [del(5q)] is associated with a favorable prognosis and a high likelihood of response to lenalidomide therapy, whereas complex karyotypes (three or more abnormalities) or monosomy 7 carry a poor prognosis and require more aggressive therapeutic interventions.

Acute Lymphoblastic Leukemia (ALL) Risk Stratification

In pediatric and adult patients diagnosed with Acute Lymphoblastic Leukemia (ALL), cytogenetic analysis is vital for risk stratification and treatment planning. Specific chromosomal abnormalities are strongly correlated with clinical outcomes. For example, high hyperdiploidy (51 to 67 chromosomes) and the t(12;21) translocation are associated with an excellent prognosis and high cure rates in children, allowing for less intensive treatment protocols to minimize long-term side effects. Conversely, the presence of the Philadelphia chromosome [t(9;22)] or rearrangements of the KMT2A (MLL) gene on chromosome 11q23 indicates high-risk disease, prompting clinicians to implement intensified chemotherapy regimens combined with targeted therapies or hematopoietic stem cell transplantation.

Unexplained Cytopenias and Bone Marrow Failure Evaluation

When patients present with persistent, unexplained cytopenias (such as severe anemia, leukopenia, or thrombocytopenia) that cannot be attributed to nutritional deficiencies, infections, or autoimmune disorders, a bone marrow evaluation is performed. Cytogenetic analysis of the bone marrow is crucial in these cases to differentiate between non-clonal reactive processes and clonal hematological disorders. The detection of a clonal chromosomal abnormality, such as a deletion or trisomy, provides definitive evidence of an underlying neoplastic process, such as early-stage myelodysplastic syndrome or an atypical myeloproliferative neoplasm, guiding the clinical team toward the correct diagnosis and management plan.

What Does a Cytogenetics (Bone Marrow Chromosomes) Detect?

The Cytogenetics (Bone Marrow Chromosomes) test is designed to detect a wide range of numerical and structural chromosomal abnormalities in hematopoietic cells, including:

• Normal Diploid Karyotype (46,XX or 46,XY): The presence of the normal complement of 46 chromosomes without detectable structural rearrangements.
• Philadelphia Chromosome [t(9;22)(q34.1;q11.2)]: The diagnostic hallmark of Chronic Myeloid Leukemia (CML) and a high-risk marker in Acute Lymphoblastic Leukemia (ALL).
• PML-RARA Translocation [t(15;17)(q24.1;q21.2)]: Diagnostic for Acute Promyelocytic Leukemia (APL), indicating sensitivity to ATRA therapy.
• RUNX1-RUNX1T1 Translocation [t(8;21)(q22;q22)]: A recurrent genetic abnormality in Acute Myeloid Leukemia (AML) associated with a relatively favorable prognosis.
• CBFB-MYH11 Inversion [inv(16)(p13.1q22)]: Associated with AML with abnormal bone marrow eosinophils, generally carrying a favorable prognosis.
• Monosomy 7 (-7): The loss of an entire chromosome 7, associated with poor prognosis in MDS and AML.
• Deletion of 7q [del(7q)]: Loss of a portion of the long arm of chromosome 7, commonly observed in myeloid neoplasms.
• Monosomy 5 (-5): The loss of an entire chromosome 5, indicating high-risk disease in MDS and AML.
• Deletion of 5q [del(5q)]: Loss of a portion of the long arm of chromosome 5, defining the “5q- syndrome” in MDS, which is highly responsive to lenalidomide.
• Trisomy 8 (+8): The presence of an extra copy of chromosome 8, a common numerical abnormality in myeloid disorders.
• Deletion of 20q [del(20q)]: A structural abnormality associated with myelodysplastic syndromes and myeloproliferative neoplasms.
• Loss of Y Chromosome (-Y): A common age-related finding in elderly males, though it can sometimes represent a clonal marker in hematological disorders.
• Isochromosome 17q [i(17q)]: A structural abnormality associated with disease progression and blast crisis in CML.
• Deletion of 17p [del(17p)]: Associated with the loss of the TP53 tumor suppressor gene, indicating a poor prognosis and resistance to standard chemotherapy in multiple hematological malignancies.
• KMT2A (MLL) Rearrangements [t(11q23)]: Involves the KMT2A gene, associated with high-risk acute leukemias in infants and adults.
• Trisomy 21 (+21): An extra copy of chromosome 21, which can be an acquired clonal abnormality in leukemia or associated with Down syndrome-related transient abnormal myelopoiesis.
• Hyperdiploidy: The presence of more than 46 chromosomes, a favorable prognostic indicator in pediatric B-cell ALL when chromosome numbers exceed 50.
• Hypodiploidy: The presence of fewer than 46 chromosomes, associated with a poor prognosis in ALL.
• Complex Karyotype: Defined as the presence of three or more unrelated clonal chromosomal abnormalities, indicating genomic instability and a poor prognosis.
• Monosomal Karyotype: Defined by the presence of at least two distinct monosomies or a single monosomy combined with a structural abnormality, carrying an extremely unfavorable prognosis in AML.
• t(12;21)(p13.2;q22.1) [ETV6-RUNX1]: The most common translocation in pediatric B-ALL, associated with a highly favorable outcome.
• t(1;19)(q23;p13.3) [TCF3-PBX1]: A translocation observed in B-ALL, historically associated with a poor prognosis but mitigated by modern intensive therapies.
• t(14;18)(q32;q21) [IGH-BCL2]: The characteristic translocation of follicular lymphoma, occasionally evaluated in bone marrow staging.
• t(11;14)(q13;q32) [CCND1-IGH]: Diagnostic translocation for mantle cell lymphoma.
• Deletion of 13q [del(13q)]: A common structural abnormality in Chronic Lymphocytic Leukemia (CLL) and Multiple Myeloma, carrying prognostic significance.
• Marker Chromosomes: Unidentified abnormal chromosomes whose origin cannot be determined by standard G-banding alone.
• Ring Chromosomes: Structural abnormalities formed when the ends of a chromosome break off and the remaining arms fuse together.
• Balanced Translocations: Reciprocal exchanges of genetic material between chromosomes without any net loss or gain of genetic information.

Turnaround Time and Report Access at Dr. Essa Lab

The Cytogenetics (Bone Marrow Chromosomes) test is a highly complex, labor-intensive diagnostic procedure. Unlike routine blood tests that yield results within hours, cytogenetic analysis requires the successful culturing of living bone marrow cells, harvesting at the precise mitotic stage, slide preparation, specialized G-band staining, and detailed manual microscopic analysis of multiple metaphase spreads by a trained cytogeneticist. At Dr. Essa Lab, the standard turnaround time for a bone marrow cytogenetics report is approximately 10 to 14 days. This timeline ensures that the cells are cultured adequately and that a thorough, medically accurate analysis is performed to provide clinicians with reliable genetic data.

Dr. Essa Lab provides convenient and secure access to diagnostic reports. Once the analysis is complete and verified by a Consultant Pathologist, the final report is uploaded to the Dr. Essa Lab online portal. Patients and referring physicians can easily access, view, and download the report using the unique patient ID and password provided on the receipt. Additionally, reports can be accessed via the official Dr. Essa Lab mobile application, ensuring that critical clinical decisions regarding patient care and treatment planning can be made without unnecessary delays.

Cytogenetics (Bone Marrow Chromosomes) Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Chromosome Number (Ploidy)	46 chromosomes (diploid state)	Aneuploidy (hyperdiploidy, hypodiploidy, monosomy, trisomy)
Chromosome Structure	No structural rearrangements, deletions, or duplications detected	Translocations, deletions, duplications, inversions, ring chromosomes, marker chromosomes
Chromosomes 9 and 22 Status	Normal morphology and independent localization	t(9;22)(q34.1;q11.2) resulting in the Philadelphia chromosome (BCR-ABL1 fusion)
Chromosomes 15 and 17 Status	Normal morphology and independent localization	t(15;17)(q24.1;q21.2) resulting in the PML-RARA fusion (diagnostic for APL)
Chromosome 5 Status	Two intact copies of chromosome 5	Monosomy 5 (-5) or deletion of the long arm [del(5q)]
Chromosome 7 Status	Two intact copies of chromosome 7	Monosomy 7 (-7) or deletion of the long arm [del(7q)]
Chromosome 8 Status	Two intact copies of chromosome 8	Trisomy 8 (+8) or structural rearrangements
Sex Chromosomes	XX (normal female) or XY (normal male)	Loss of Y chromosome (-Y), structural abnormalities of X or Y
Clonal Evolution	Single normal cell line (no clonal abnormalities)	Multiple related or unrelated abnormal clones indicating disease progression

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Dr. Essa Lab for Cytogenetics (Bone Marrow Chromosomes)?

• Accredited Diagnostic Excellence: Dr. Essa Lab is a highly trusted diagnostic network in Pakistan, recognized for its commitment to international quality standards and accurate testing.
• Expert Pathologists and Geneticists: The cytogenetics department is led by experienced consultant pathologists and clinical geneticists who ensure precise interpretation of complex karyotypes.
• Advanced Cytogenetic Infrastructure: Equipped with state-of-the-art automated karyotyping systems and high-resolution imaging software to minimize human error and enhance diagnostic precision.
• Comprehensive Hematopathology Services: Offers integrated diagnostic pathways combining bone marrow morphology, flow cytometry, cytogenetics, and molecular testing (PCR/FISH) for a complete diagnostic picture.
• Rigorous Quality Control: Participates in external quality assurance programs to maintain the highest level of diagnostic accuracy and reliability in genetic testing.
• Convenient Online Portal: Patients and clinicians can access secure digital reports from anywhere via the website or mobile app, facilitating timely clinical interventions.
• Extensive Collection Network: With numerous branches across Karachi and other major cities, patients have easy access to professional sample collection and diagnostic services.
• Patient-Centric Care: Prioritizes patient comfort, safety, and clear communication throughout the diagnostic journey, ensuring a supportive environment for complex testing.